Overcoming poor permeability - The role of prodrugs for oral drug delivery

Drug Discovery Today: Technologies

Volumn 9, Issue 2, 2012, Pages

  Maag, Hans ^a  

^a Chemistry and Drug Discovery Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 2' FLUORO 2' METHYLCYTIDINE; AMIDINE; CARBOXYLIC ACID; FLAVONOID; GEMCITABINE; GUANIDINE DERIVATIVE; HEAT SHOCK PROTEIN 90 INHIBITOR; HETEROCYCLIC COMPOUND; MELAGATRAN; NUCLEOSIDE DERIVATIVE; PERZINFOTEL; PHOSPHORAMIDIC ACID DERIVATIVE; PRODRUG; SNX 2112; SNX 5422; SOFOSBUVIR; TENOFOVIR; UNCLASSIFIED DRUG; XIMELAGATRAN;

ARTICLE; CYCLIZATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; HEPATITIS C; HUMAN; LIPOPHILICITY; ORAL DRUG ADMINISTRATION; PROCESS OPTIMIZATION; RISK ASSESSMENT;

EID: 84873084089     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2012.04.002     Document Type: Review

References (30)

1. Amidon, G.L. et al. (1995) A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420
2. A number of comprehensive reviews have been published: a. Rautio, J., ed. (2011) Prodrugs and Targeted Delivery, Volume 47 in Methods and Principles in Medicinal Chemistry.Wiley-CH;
3. Stella, V.J. et al., ed. (2007) Prodrugs: Challenges and Rewards, Vol. 5 in Biotechnology: Pharmaceutical Aspects. Springer-AAPS Press;
4. Boddu, S.H.S. et al. (2011) Prodrug strategies to enhance oral drug absorption. In Oral Bioavailability: Basic Principles, Advanced Concepts, and Applications (Hu,M., Li, X., eds)), John Wiley & Sons
5. Maag, H. (2007) Prodrugs of carboxylic acids. In Prodrugs: Challenges and Rewards, Volume 5 in Biotechnology: Pharmaceutical Aspects. Part 2 (Stella, V.J. et al. eds), pp. 3-29, Springer-AAPS Press
6. Marquis, R.W. et al. (2009) Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues. J. Med. Chem. 52, 6599-6605
7. Liederer, B.M. and Borchardt, R.T. (2006) Enzymes involved in the bioconversion of ester-based prodrugs. J. Pharm. Sci. 95, 1177-1195
8. Huang, K.H. et al. (2009) Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J. Med. Chem. 52, 4288-4305
9. The pKa of glycine ethyl ester was measured to be 7.74 at 258C: Robson, M. (1965) Protonation equilibria and alkaline hydrolysis of glycine ethyl ester. Nature 208, 265-267
10. Tilley, J.W. (2007) Prodrugs of benzamidines. In Prodrugs: Challenges and Rewards, Volume 5 in Biotechnology: Pharmaceutical Aspects, Part 2 (Stella, V.J. et al. eds), pp. 189-222, Springer-AAPS Press
11. Sorbera, L.A. et al. (2001) Melagatran and ximelagatran. Drugs Future 26, 1155
12. Reeh, C. et al. (2007) N,N′-Dihydroxyamidines: a new prodrug principle to improve the oral bioavailability of amidines. J. Med. Chem. 50, 6730-6734
13. Bailey, P.D. et al. (2000) How to make drugs orally active: a substrate template for peptide transporter PepT1. Angew. Chem. Int. Ed. 39, 506-508
14. Sun, J. et al. (2010) Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach. J. Med. Chem. 53, 624-632
15. Huttunen, K.M. et al. (2009) The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption. J. Med. Chem. 52, 4142-4148
16. DiMauro, T.M. (2011) Metformin-cysteine prodrug. US Pat. Appl. 20110257432 A1
17. Hirpara, K.V. et al. (2009) Quercetin and its derivatives: synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability. Anti-Cancer Agents Med. Chem. 8, 138-161
18. Ninomiya, M. et al. (2011) Increased bioavailability of tricin-amino acid derivatives via a prodrug approach. J. Med. Chem. 54, 1529-1536
19. Kim, K.M. et al. (2009) In vitro solubility, stability and permeability of novel quercetin-amino acid conjugates. Bioorg. Med. Chem. 17, 1164-1171
20. Li, F. et al. (2007) Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J. Pharm. Sci. 1-26
21. Song, X. et al. (2004) Amino acid ester prodrugs of the anticancer agent Gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol. Pharm. 2, 157-167
22. Bender, D.M. et al. (2009) Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J. Med. Chem. 52, 6958-6961
23. Jonckers, T.H.M. et al. (2010) 2′-Deoxy-2′- spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase. J. Med. Chem. 53, 8150-8160
24. Naesens, L. et al. (1998) Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2- phosphonylmethylpropyl)adenine in mice. Antimicrob. Agents Chemother. 42, 1568-1573
25. Mehellou, Y. et al. (2009) Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells. ChemMedChem 4, 1779-1791
26. Sofia, M.J. et al. (2010) Discovery of a b-D-2′-deoxy-2′-a- fluoro-2′-b-Cmethyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 53, 7202-7218
27. McGuigan, C. et al. (2011) Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti- HCV agents. J. Med. Chem. 54, 8632-8645
28. Baudy, R.B. et al. (2009) Prodrugs of perzinfotel with improved oral bioavailability. J. Med. Chem. 52, 771-778
29. Dhareshwar, S. and Stella, V.J. (2008) Your prodrug releases formaldehyde: Should you be concerned? No! J. Pharm. Sci. 97, 4184-4193
30. Dang, Q. et al. (2011) Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase. J. Med. Chem. 54, 153-165